Data From ASCO 2024: Exposure-Response Analysis of Trastuzumab Deruxtecan to Inform Dosing in Patients With HER2-Mutated NSCLC

Subscribe

Data From ASCO 2024: Exposure-Response Analysis of Trastuzumab Deruxtecan to Inform Dosing in Patients With HER2-Mutated NSCLC

Rapid Reactions

ASCO 2024 HER2-Mutated NSCLC

Videos

Amanda L. Brink, DNP, APRN, FNP-BC, AOCNP, discusses results from an exposure-efficacy and exposure-safety analysis of trastuzumab deruxtecan in patients with HER2-mutated NSCLC. In her recap, she highlights the importance of education around dose adjustments to manage patient expectations.

Amanda L. Brink, DNP, APRN, FNP-BC, AOCNP
Advanced Practice Registered Nurse
Department of Investigational Cancer Therapeutics
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

TON Print Edition

TON Weekly e‑Newsletter

I have reviewed and consent to the terms of TON's Privacy Policy, and TON has my permission to retain my information in its database, and to forward pertinent communications to me.

Subscribe to receive the free, TON print publication, and TON Bi-Weekly e‑newsletter.

Subscribe

Data From ASCO 2024: Exposure-Response Analysis of Trastuzumab Deruxtecan to Inform Dosing in Patients With HER2-Mutated NSCLC

Related Items

Subscribe Today!

I'd like to receive:

We Value Your Feedback! Tell Us How You Consume Content